Here we go off again |
I remember that being the case when I was looking into these. It's above 7p now 16p fair value here in the very short term. He f knows where it will hit when the FDA goes through for the American market :D |
I would expect it to go above 10p easily, not many shares |
I added more as soon as I could this morning. Can sell my whole holding at 7p if this doesn't hit 10p today I'll be very surprised |
10pnext stop, massive news |
Next leg incoming ;) |
That's like pulling a fit bird on a one night stand and nailing her once my friend... you want to go again and again... at least 3 times ... you'll be trying to jump back on later when I'm still nailing her ;) |
Already done bagged and out |
It's a nailed on this will bag today.... Been way undervalued for a while. I've been buying for a while now it wouldn't suprised me if it quickly surpasses 8p today may even see 2 bags! FDA can't be long away which is what I'm holding out for. |
Gone NT to buy @ 6p |
Share price could easily RISE over 200% just like EXR did yesterday |
8p to 10p on this news |
3p was mega cheap here tbf under 8p is cheap here ;) |
Another undervalued stock likely to RISE over 100% just like EXR , BANK , IMM , TRLS |
At GENinCode we have developed a clinical-genetic test that is part of the prevention of Ischemic Heart Disease, and a simple saliva sample is sufficient. This clinical-genetic test is called CARDIO inCode® Score, and it combines one's genetic predisposition to develop a [CI] with one's lifestyle.The evidence is very encouraging: the companies that choose us observe a reduction of more than 50% in the attendance rate of leave for cardiovascular disease.SourceCarlos Iribarren, Meng Lu, Roberto Elosua, Martha Gulati, Nathan D. Wong, Roger S. Blumenthal, Steven Nissen, Jamal S. Rana, Polygenic risk and incident coronary heart disease in a large multiethnic cohort, American Journal of Preventive Cardiology, Volume 18, 2024, 100661, ISSN 2666-6677 |
5th December NHS2 buyersNewcastle Upon Tyne Hospitals NHS TrustNewcastle upon Tyne1 supplierGenincodeOxfordDescriptionTo provide Genetic testing for Familial Hypercholesterolaemia (FH) from provided sample taken by TrustTotal Quantity or ScopeTo provide Genetic testing for Familial Hypercholesterolaemia (FH)Award DetailGenincode (Oxford)Num offers: 1Value: £405,000Contractor is an SME. |
* UK VC funding at Series A is -44% from last year, and worsening* Q3 24 is down a staggering 57% from Q2, itself down from Q1* 9 in 10 seed funded startups cannot access Series A VC funding, the next 'rung on the funding ladder'* Just 32 future scaleup companies across the whole of the UK were able to access their first VC funding round in Q3...a 6 year low* Half a billion less capital is going in to UK scaleups at Series A, than just 2 years agoOur independent research here, for the UK ScaleUp Investment Mission, is laser beam focussed on Series A. The funding round where companies move from the c.1m startups launched each year, through the 2,179 that access seed funding, into the rarefied category of being recognised as future scaleups, attracting Series A funding (£2-10m). The UK venture landscape is currently funding just 248 pa of these companies, and declining. |
I thought Mathew was justifiably up-beat this afternoon. |
Nothing - a dot means I push posts I have filtered out of the way so I know if there is something worth reading. |
What is wrong with you? |
Some poor f..k bought £6K for 8.20,oops. |
Time to bale people,back to under 7 by the looks of it. |
The rampers have now arrived on LSE,plus no large buys to indicate a leak so I sold on the spike,hope I right,but if it keeps rising good luck to you,I happy with my profits. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
